249 related articles for article (PubMed ID: 30008477)
21. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
Farhadfar N; Li Y; May WS; Adams CB
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):246-251. PubMed ID: 32199933
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Algarín EM; Díaz-Tejedor A; Mogollón P; Hernández-García S; Corchete LA; San-Segundo L; Martín-Sánchez M; González-Méndez L; Schoumacher M; Banquet S; Kraus-Berthier L; Kloos I; Derreal A; Halilovic E; Maacke H; Gutiérrez NC; Mateos MV; Paíno T; Garayoa M; Ocio EM
Haematologica; 2020 Mar; 105(3):e116-e120. PubMed ID: 31320555
[No Abstract] [Full Text] [Related]
23. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
25. The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance.
Ariës IM; Hansen BR; Koch T; van den Dungen R; Evans WE; Pieters R; den Boer ML
Haematologica; 2013 Dec; 98(12):1905-11. PubMed ID: 24142999
[TBL] [Abstract][Full Text] [Related]
26. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Tarantelli C; Zhang L; Curti E; Gaudio E; Spriano F; Priebe V; Cascione L; Arribas AJ; Zucca E; Rossi D; Stathis A; Bertoni F
Haematologica; 2019 Jul; 104(7):e307-e309. PubMed ID: 30679329
[No Abstract] [Full Text] [Related]
27. Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax.
Trinder SM; Soggee J; Spragg J; Alexander D; Mitchell R; Gottardo NG; Ramachandran S
Pediatr Blood Cancer; 2024 Mar; 71(3):e30841. PubMed ID: 38149837
[No Abstract] [Full Text] [Related]
28. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
[No Abstract] [Full Text] [Related]
29. Mediastinal Gamma-Delta T-Cell Lymphoblastic Lymphoma Successfully Treated With Chemotherapy Alone.
Fujino H; Nii S; Sumimoto S
J Pediatr Hematol Oncol; 2021 Apr; 43(3):117-118. PubMed ID: 33370002
[No Abstract] [Full Text] [Related]
30. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
Opydo-Chanek M; Rak A; Cierniak A; Mazur L
Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Wan CL; Zou JY; Qiao M; Yin J; Shen XD; Qiu QC; Liu SB; Xue SL
Leuk Lymphoma; 2021 Dec; 62(13):3300-3303. PubMed ID: 34323656
[No Abstract] [Full Text] [Related]
32. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
34. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
35. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
37. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
[No Abstract] [Full Text] [Related]
39. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
[TBL] [Abstract][Full Text] [Related]
40. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(
Florean C; Kim KR; Schnekenburger M; Kim HJ; Moriou C; Debitus C; Dicato M; Al-Mourabit A; Han BW; Diederich M
Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30572618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
